TCRX TScan Therapeutics, Inc.: Earnings per share for the trailing year
This chart of the current market value of TScan Therapeutics (TCRX) demonstrates the 20.70 indicator. TScan Therapeutics (TCRX) strictly adheres to bio-waste disposal regulations. The business relies on the development of T-cell tumor treatments, although a lack of sales and R&D expenses hinder profit growth. The project's success is based on the precision of target identification within cells and market confidence in the results of primary safety tests.
%20TScan%20Therapeutics%2C%20Inc.&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_TCRX_-_TScan-Therapeutics_-_Net-earnings-per-share-EPS-TTM "TCRX (tscan.com) Net earnings per one share for the last twelve months history from 02/11/2024 to 11/15/2026 | 👁️GURU.Markets👁️")
TScan Therapeutics, Inc. - analytical breakdowns and key metrics (TCRX)
- current quotes and average value forecast:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Coefficient TScan Therapeutics|TCRX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio tscan.com|TCRX - Company Aggregate Debts|Debts to Book Capitalization TCRX|TCRX - Company Long-Term Debt|Company Short-Term Indebtedness TScan Therapeutics|Intermediate Coverage Ratio tscan.com
- net income and valuation ratios data:
TCRX - Net Income|Future Net Profit TScan Therapeutics|TCRX - P/E Multiple|Future Price to Earnings Multiple tscan.com|TCRX - PEG Multiple|Company Value to EBITDA TCRX|TCRX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year TScan Therapeutics|TCRX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth tscan.com|TCRX - Earnings per share growth in current year|Net earnings per share change forecast for next year TScan Therapeutics
- sales volume and revenue information:
Fundamental company valuation:TCRX - TScan
This indicator measures the trailing twelve-month (TTM) net income per share, neutralizing time gaps between quarterly reports to assess earnings growth rates. By analyzing the year-over-year change in EPS (TTM), an investor can evaluate the sustainability of the TScan Therapeutics (TCRX) business model, where massive R&D expenditures and the patent protection of the Barriers platform determine the asset's long-term fundamental value.
Competitor analysis
Earnings per share for the trailing year ONC (BeiGene)|Halozyme Inc. (HALO) - Earnings per share for the last twelve months|RevMed - Earnings per share for the trailing year|AAPG (Ascentage Pharma Group International) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology, Inc. CGON|Net earnings per share for the last 12 months URGN (urogen.com)|Earnings per share for the last twelve months BCAX (Bicara Therapeutics)|Net earnings per share (EPS TTM) PSNL (personalis.com)|Earnings per share for the trailing year ERAS|DCTH - Earnings per share for the last twelve months|Y-mAbs Therapeutics (YMAB) - Net earnings per share for the last 12 months|AURA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CADL|Earnings per share for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ACTU (Actuate Therapeutics, Inc)|Net earnings per share for the last four quarters Citius Oncology|TuHURA Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Protara TARA|fatetherapeutics.com - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aadi Bioscience|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|SBFM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XBIO|Salarius (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Ltd. (PPBT)|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months NAYA Bio (NAYA)|AAPGV: Earnings per one share for the last 12 months
